More on why cholesterol drugs, specifically CETP inhibitors, might prevent or treat Alzheimer’s and Lewy Body Dementia (LBD), especially in ApoE4’s.
(Note that ApoE4 raises the risk for Lewy Body Dementia, as well as Alzheimer’s.)
Quoted:
Why would a cholesterol drug touch the brain? Because APOE is the main cholesterol-carrier protein in your brain. Block CETP, raise HDL particles AND the ApoE riding on them, and synthetic HDL clears amyloid from brain vessels (mouse data). And genetics predicted it: Mendelian randomization in 2024 showed the CETP benefit was MOST PRONOUNCED in APOE4+ carriers. LBD odds ratio 0.61 in APOE4+ vs 0.89 in non-carriers, interaction p = 5.81 x 10^-4. 2006 Barzilai centenarians: CETP VV variant doubled odds of MMSE > 25. 2015 Cache County: CETP I405V slowed cognitive decline by 0.6 points/year per valine. Note: Cache County did NOT link CETP I405V to Alzheimer's diagnosis — trajectory not disease prevention. Convergence across 20 years of genetics, MR, and now a Phase 3 biomarker readout.
Full breakdown at the link in bio.
#cetpinhibitorHD #apoe4HD #alzheimersHD #dementiaHD #hdlHD #obicetrapibHD #lewybodydementiaHD


